Online inquiry

IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10484MR)

This product GTTS-WQ10484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CALCA&CALCB gene. The antibody can be applied in Osteoarthritis (OA), Migraine, Cluster headache (CH) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001033952.3; NM_000728.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 796; 797
UniProt ID P01258; P10092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ10484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12107MR IVTScrip™ mRNA-Anti-FOLR1, MORAb-003(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MORAb-003
GTTS-WQ14776MR IVTScrip™ mRNA-Anti-CD40, SGN-40(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-40
GTTS-WQ12643MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ15693MR IVTScrip™ mRNA-Anti-VEGFA, VEGF Trap(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA VEGF Trap
GTTS-WQ939MR IVTScrip™ mRNA-Anti-EGFR, ABBV-321(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-321
GTTS-WQ1241MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ15869MR IVTScrip™ mRNA-Anti-CD19, XmAb5871(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA XmAb5871
GTTS-WQ11404MR IVTScrip™ mRNA-Anti-PDGFRA, MEDI-575(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MEDI-575
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW